Molecular Genetics of Human Leucocyte Antigen in Diseases

Dear Colleagues,

Classical HLA (Human Leukocyte Antigen) is the Major Histocompatibility Complex (MHC) present in humans. The association between HLA genes and diseases has been studied since 1967, and no definite pathogenic mechanisms have been established yet. The study of HLA-G immune modulation gene (and also of -E and -F) has began in the same arduous way, where statistics and allele association are the trending subjects, with the same few results being obtained by HLA classical genes, i.e., no pathogenesis has been discovered after several years of tremendous research efforts. Thus, we believe that it is necessary to follow different research methodologies: (1) to approach this problem based on how evolution has maintained together a cluster of immune-related genes (the MHC) in a relatively short chromosome area from the evolution of amniotes to humans, i.e., immune-regulatory genes (MHC-G, -E and -F), adaptive immune classical class I and II genes, non-adaptive immune genes like C2, C4 and Bf, and (2) to propose the allelism of complement factors for studying MHC complement genes, complotypes, and extended MHC haplotypes, which may be more informative that single MHC marker studies.

This Special Issue of the International Journal of Molecular Sciences on “Molecular Genetics of Human Leucocyte Antigen in Diseases”, assisted by Profs Ignacio Juarez (Universidad Complutense de Madrid, Madrid, Spain) and Fabio Suarez-Trujillo（Universidad Complutense de Madrid, Madrid, Spain), aims at providing new approaches to decipher the cause of HLA/MHC and addressing disease association problems. Data on molecular mechanisms or pathophysiology are essential, and papers that only contain clinical trials/data will not be accepted.

Prof. Dr. Antonio Arnaiz-Villena
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• HLA
• HLA-G
• HLA-E
• HLA-F
• disease
• MHC evolution
• autoimmunity
• haemochromatosis
• narcolepsy
• complement
• autoimmunity